润科生物品牌怎么样 申请店铺

我要投票 润科生物在DHA藻油行业中的票数:715 更新时间:2025-12-13
润科生物是哪个国家的品牌?「润科生物」是 广东润科生物工程股份有限公司 旗下著名品牌。该品牌发源于广东省汕头市,由创始人陈 *在2000年期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力润科生物品牌出海!将品牌入驻外推网,定制润科生物品牌推广信息,可以显著提高润科生物产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

润科生物怎么样

广东润科生物工程股份有限公司于2000年5月创立于广东汕头,是一家应用现代生物工程技术进行研发、生产源于海洋微藻的人类健康产品的企业。公司成立以来一直专注于研发、生产和销售食品强化剂,利用生物工程技术培养富含DHA(二十二碳六烯酸)海洋微藻、培育高含量ARA(花生四烯酸)细胞,并分别提取DHA营养强化剂和ARA营养强化剂,主要产品为DHA藻油、DHA粉剂、ARA油脂、ARA粉剂、DHA+ARA混合粉。DHA属于N-3系多不饱和脂肪酸,能促进脑细胞的生长和神经网络的形成,有利于智力与神经的改善;ARA属于N-6系多不饱和脂肪酸,有利于体格的发育。

广东润科生物工程股份有限公司成立之后,研发成功突破了微藻DHA关键技术,是世界上较早拥有微藻DHA生产关键技术的生产厂家之一。公司同时也是ARA专业生产商。公司以市场为导向,依靠技术创新,始终坚持以高稳定性、高纯净度为质量目标,主要研究方向是DHA和ARA产品的开发及其在乳制品行业、粮油行业、食品行业、保健品行业中的添加及拓展应用。

在技术创新方面,公司迄今获得国家发明专利18项,实用新型专利28项,外观设计专利2项,已受理申请发明专利17项,已受理申请实用新型专利1项;科技成果转化方面,共承担科研项目6项,省市科技厅、经贸厅、发改委、知识产权局项目18项。公司参与已发布实施的国家标准《食品添加剂 二十二碳六烯酸油脂(发酵法)》和《食品添加剂 花生四烯酸油脂(发酵法)》的起草制定,参与已发布实施的行业标准《DHA藻油》的起草制定。

在研发方面,公司先后承担了国家创新基金项目“利用生物反应器高密度异养培养海洋微原生生物生产DHA微藻”、国家火炬计划项目“40吨级发酵罐异养培养富含DHA海洋微藻”、国家创新基金项目“微藻DHA在食品领域中的推广应用”、福建省发改委618优秀项目“利用海洋微藻异养培养技术生产长链多不饱和脂肪酸DHA微藻油产业化示范”;公司目前拥有“汕头市海洋微藻及真菌微生物应用研究工程技术研究开发中心”、“漳州市企业技术创新中心”、“广东省省级企业技术中心”、“广东省海洋微藻生物工程技术研究开发中心”、“福建省海洋微藻培育及功能成分开发企业工程技术研究中心”等多个省市级的技术研究开发中心。研发团队以博士、硕士研究生和高级工程师为主,公司研发总监姜悦为国家“千人计划”创新人才,系微生物和食品生物技术专家,在微生物工程、微藻生物资源技术、食品生物及食用天然产物功能因子结构和表征等方面研究成果显著。

在质量保证方面,公司秉持“质量就是企业生命之本”的原则,采取全员、全环节的质量控制手段。公司分别通过ISO9001质量管理体系认证、HACCP-EC-01食品安全管理体系认证、ISO22000食品安全管理体系认证、ISO14001环境管理体系认证、HACCP危害分析与关键控制点体系认证。

公司产品以优质的质量保证分别通过STAR-K颁发的Kosher犹太认证、印度尼西亚乌拉玛委员会(简称MUI)的HALAL清真认证、欧盟新资源食品(简称NOVEL FOOD)爱尔兰食品安全局的普通食品领域的实质等同(SE)认证、欧洲饲料添加剂和预混合饲料行业协会(简称FAMI)的QS管理体系认证、美国国家卫生基金会(简称NSF)的GMP认证、美国食药局(简称FDA)的GRAS普通食品领域认证、欧盟新资源食品(简称NOVEL FOOD)爱尔兰食品安全局的婴配领域的实质等同(SE)认证、美国食药局(简称FDA)的GRAS婴配领域的认证。公司目前与国内多家乳制品企业,如蒙牛、伊利、贝因美、君乐宝、完达山、飞鹤、光明、雅士利、羊羊100、百跃羊乳、明一等建立了业务合作关系,同时拓展了海外市场。


Guangdong runke Bioengineering Co., Ltd. was founded in Shantou, Guangdong Province in May 2000. It is an enterprise that applies modern bioengineering technology to develop and produce human health products derived from marine microalgae. Since its establishment, the company has been focusing on the research and development, production and sales of food fortifiers. It uses bioengineering technology to cultivate marine microalgae rich in DHA (docosahexaenoic acid) and high-content ara (arachidonic acid) cells, and extracts DHA nutritional fortifier and Ara nutritional fortifier respectively. Its main products are DHA algal oil, DHA powder, Ara oil, Ara powder and DHA + ara mixed powder. DHA belongs to n-3 polyunsaturated fatty acids, which can promote the growth of brain cells and the formation of neural networks, and is conducive to the improvement of intelligence and nerves; ara belongs to n-6 polyunsaturated fatty acids, which is conducive to physical development. After the establishment of Guangdong runke Bioengineering Co., Ltd., it has successfully broken through the key technology of microalgae DHA, and is one of the earliest manufacturers in the world with key technology of microalgae DHA production. The company is also a professional manufacturer of Ara. The company is market-oriented, relying on technological innovation, and always adheres to the quality goal of high stability and high purity. Its main research direction is the development of DHA and Ara products and their addition and expansion in the dairy industry, grain and oil industry, food industry and health care industry. In terms of technological innovation, the company has so far obtained 18 national invention patents, 28 utility model patents, 2 design patents, 17 invention patents and 1 utility model patent; in terms of transformation of scientific and technological achievements, the company has undertaken 6 scientific research projects, 18 projects of provincial and municipal science and technology departments, economic and trade departments, development and Reform Commission and intellectual property office. The company participated in the drafting and formulation of the national standards "food additive docosahexaenoic acid oil (fermentation law)" and "food additive arachidonic acid oil (fermentation law)", and participated in the drafting and formulation of the industry standard "DHA algae oil" which has been issued and implemented. In terms of research and development, the company has successively undertaken the national innovation fund project of "using bioreactor to cultivate marine micro protozoa with high density heterotrophic cultivation to produce DHA microalgae", the national Torch Program project of "heterotrophic cultivation of marine microalgae rich in DHA in 40 ton fermentor", the national innovation fund project of "promotion and application of microalgae DHA in the food field", and the outstanding project of Fujian Provincial Development and Reform Commission 618 At present, the company has "Shantou engineering technology research and development center of marine microalgae and fungi application research", "Zhangzhou enterprise technology innovation center", "Guangdong provincial enterprise technology center", "Guangdong marine microalgae bioengineering technology research and development center", and "Guangdong marine microalgae bioengineering technology research and development center" Many provincial and municipal technology research and development centers, such as Xin, Fujian engineering technology research center of marine microalgae cultivation and functional component development enterprises. The R & D team is mainly composed of Ph.D., master's degree and senior engineer. Jiang Yue, director of R & D of the company, is a national "thousand talents plan" innovation talent. He is an expert in Microbiology and food biotechnology. He has made remarkable research achievements in microbial engineering, microalgae biological resource technology, food biology and functional factor structure and characterization of edible natural products. In terms of quality assurance, the company adheres to the principle of "quality is the foundation of enterprise life", and adopts all staff and all links of quality control means. The company has passed ISO9001 quality management system certification, haccp-ec-01 food safety management system certification, ISO22000 food safety management system certification, ISO14001 environmental management system certification, HACCP hazard analysis and key control point system certification. The company's products have passed kosher Jewish certification issued by star-k, halal halal certification issued by Ulama Committee of Indonesia (MUI), substance of general food field of Irish food safety agency of new resources food of European Union (novelfood), QS management of European feed additive and premixed feed industry association (fami) Physical system certification, GMP certification of NSF, gras general food certification of FDA, Se certification of novelfood, and gras infant formula certification of FDA. At present, the company has established business cooperation with many domestic dairy products enterprises, such as Mengniu, Yili, beiinmei, JUNLEBAO, Wandashan, Feihe, Guangming, Yashili, Yangyang 100, Baiyue Yangru, Mingyi, etc., and expanded overseas market.

本文链接: https://brand.waitui.com/3a5a86006.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

美股三大指数集体收跌,大型科技股多数下跌

36氪获悉,12月12日收盘,美股三大指数集体下跌,道指跌0.51%,纳指跌1.69%,标普500指数跌1.07%。 大型科技股多数下跌,甲骨文、英特尔跌超4%,英伟达跌超3%,亚马逊、Meta、微软、谷歌跌超1%;特斯拉涨超2%,奈飞涨超1%。热门中概股涨跌不一,网易、新东方涨超2%,知乎、斗鱼涨超1%;爱奇艺跌超4%,百度跌超2%,哔哩哔哩、老虎证券跌超1%。

2小时前

SpaceX敲定内部股票交易,估值约达8000亿美元

北京时间12月13日早间消息,一份公司文件显示,太空探索技术公司(SpaceX)已批准一项内部股票交易,该交易对埃隆·马斯克旗下这家火箭与卫星制造企业的估值定为约8000亿美元。此次次级发行将为包括员工在内的股东提供套现或增持股票的机会。媒体此前报道,这是该公司计划最早于2026年进行首次公开募股(IPO)的前期准备动作。该公司同时表示,正在为2026年可能开展的公开上市做准备。(新浪财经)

2小时前

美银认为美联储国库券购买操作或令10年期美债收益率承压

美国银行的利率策略师表示,美联储为维持银行体系现金充裕而购买国库券,有可能会抑制长期收益率。华尔街的策略师普遍预期,美联储的准备金管理购买(RMP)操作 —— 加上其10月决定动用资产负债表上的抵押贷款支持证券收益购买国库券 —— 将在未来一年内吸收大部分国库券净供应量。(财联社)

2小时前

纳斯达克100指数调整,纳入6家公司

当地时间12月12日,纳斯达克公布纳斯达克100指数年度成分股调整结果,调整将于2025年12月22日(星期一)开盘前生效。以下六家公司将被纳入该指数:Alnylam Pharmaceuticals、Ferrovial、Insmed、Monolithic Power Systems、Seagate和Western Digital。(界面)

2小时前

摩尔线程回应“闲置募集资金现金管理”:不影响募投项目实施,实际现金管理金额将明显小于上限

关于摩尔线程昨晚发布的拟使用不超过75亿元的部分闲置募集资金进行现金管理的公告,其相关负责人回应称:公司前期明确披露了募集资金的项目计划,所募75亿资金有分阶段、明确的研发、技术升级等一系列使用安排,也将严格按照既定募投项目计划的推进。“本次审议的75亿元为现金管理额度上限,并非实际现金管理金额。实际现金管理金额将明显小于上限,后续随着募投项目逐步推进,以及置换前期自有资金投入募投项目的金额,闲置资金规模将相应减少,现金管理额度也会随之动态下降。”该负责人表示,公司将持续加大研发投入,以加速产品快速迭代、攻坚核心技术壁垒,并构建自主可控的技术与产品体系,绝不会因现金管理影响募投项目的正常实施和公司主营业务的正常发展。(财联社)

2小时前

本页详细列出关于润科生物的品牌信息,含品牌所属公司介绍,润科生物所处行业的品牌地位及优势。
咨询